scPharmaceuticals Inc. financial data

Symbol
SCPH
Location
Burlington, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 07 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 594% % -13%
Quick Ratio 91% % 9.7%
Debt-to-equity 2196% % 1077%
Return On Equity -2086% % -934%
Return On Assets -91% % -29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53,298,296 shares 6.5%
Common Stock, Shares, Outstanding 53,290,227 shares 47%
Common Stock, Value, Issued $5,000 USD 25%
Weighted Average Number of Shares Outstanding, Basic 53,719,662 shares 38%
Weighted Average Number of Shares Outstanding, Diluted 53,719,662 shares 38%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue $15,758,000 USD 127%
Research and Development Expense $15,424,000 USD 27%
Operating Income (Loss) $66,540,000 USD -10%
Net Income (Loss) Attributable to Parent $91,716,000 USD -51%
Earnings Per Share, Basic -1 USD/shares -17%
Earnings Per Share, Diluted -1 USD/shares -17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $40,809,000 USD 6%
Accounts Receivable, after Allowance for Credit Loss, Current $19,409,000 USD 217%
Inventory, Net $14,573,000 USD -4.8%
Assets, Current $78,729,000 USD 26%
Property, Plant and Equipment, Net $48,000 USD 2.1%
Operating Lease, Right-of-Use Asset $1,175,000 USD -10%
Assets $80,255,000 USD 23%
Accounts Payable, Current $4,026,000 USD -24%
Employee-related Liabilities, Current $4,137,000 USD 29%
Accrued Liabilities, Current $16,082,000 USD 117%
Liabilities, Current $20,430,000 USD 58%
Operating Lease, Liability, Noncurrent $984,000 USD -17%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $101,571,000 USD 81%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD
Retained Earnings (Accumulated Deficit) $404,260,000 USD -29%
Stockholders' Equity Attributable to Parent $21,316,000 USD -330%
Liabilities and Equity $80,255,000 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $17,139,000 USD 3.2%
Net Cash Provided by (Used in) Financing Activities $972,000 USD
Net Cash Provided by (Used in) Investing Activities $29,319,000 USD 319%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 53,290,227 shares 47%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $18,111,000 USD -256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40,809,000 USD 6%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,385,000 USD -5.7%
Deferred Tax Assets, Valuation Allowance $94,093,000 USD 29%
Deferred Tax Assets, Gross $94,427,000 USD 27%
Operating Lease, Liability $1,248,000 USD -9.2%
Depreciation $17,000 USD -26%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $91,716,000 USD -51%
Lessee, Operating Lease, Liability, to be Paid $1,565,000 USD -15%
Property, Plant and Equipment, Gross $136,000 USD 14%
Operating Lease, Liability, Current $264,000 USD 39%
Lessee, Operating Lease, Liability, to be Paid, Year Two $367,000 USD 5.2%
Lessee, Operating Lease, Liability, to be Paid, Year One $384,000 USD 13%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $317,000 USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Three $369,000 USD 3.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $1,383,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Four $249,000 USD -32%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $5,325,000 USD -5.4%
Interest Expense $6,121,000 USD -27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%